Theriva Biologics To Present Preclinical Data For Potential Synergy Of VCN-01 And First-Line Pancreatic Cancer Chemotherapy Regimens At American Society For Cell And Gene Therapy 27th Annual Meeting
Theriva Biologics To Present Preclinical Data For Potential Synergy Of VCN-01 And First-Line Pancreatic Cancer Chemotherapy Regimens At American Society For Cell And Gene Therapy 27th Annual Meeting
Theriva Biologics 將在美國細胞與基因療法學會第 27 屆年會上提供臨床前數據，探討 VCN-01 和一線胰腺癌化療方案的潛在協同作用
– Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft–
— 主要候選產品，VCN-01 與脂質體伊立替康聯合在人胰腺小鼠異種移植中顯示出增強的抗腫瘤作用—
– The observed synergy emphasizes VCN-01's potential in diverse chemotherapy combinations for improved efficacy in the treatment of pancreatic cancer–
— 觀察到的協同作用凸顯了 VCN-01 在多種化療組合中提高胰腺癌治療療效的潛力—
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間